News | Celsius Therapeutics

2020
2019
2018

December 21

Servier and Celsius Therapeutics Announce Target Discovery Collaboration in Colorectal Cancer

PARIS, France and CAMBRIDGE, Mass., US – December 21st, 2020 – Servier, a global pharmaceutical Group, and Celsius Therapeutics, a company focused on bringing precision medicine to patients with cancer and autoimmunity, today announced a strategic collaboration focused on the identification and validation of novel colorectal cancer (CRC) drug targets. “As colorectal cancer remains a leading contributor […]
July 1

Celsius Therapeutics Signs Research Agreements with Leading Academic Centers to Develop Insights into Inflammatory Bowel Disease Biology

CAMBRIDGE, Mass., July 1, 2020 – Celsius Therapeutics, a company focused on bringing precision medicine to patients with autoimmunity, cancer and other complex diseases, today announced the signing of three collaboration agreements with the University of Oxford (Oxford, UK), Cleveland Clinic (Cleveland, U.S.) and the LMU University Hospital Munich (Munich, Germany). In each agreement, Celsius […]
May 12

Jeanne Magram, Ph.D., Appointed to Chief Scientific Officer & René Russo, Pharm.D., Joins Board of Directors

Cambridge, MA – May 12, 2020 – Celsius Therapeutics, a company focused on bringing precision medicine to patients with cancer, autoimmunity and other complex diseases, today announced the appointment of Jeanne Magram, Ph.D., to chief scientific officer. Christoph Lengauer, Ph.D., a partner at Third Rock Ventures and co-founder and former interim chief scientific officer of […]

September 23

FierceBiotech names Celsius Therapeutics as one of its “Fierce 15” Biotech Companies of 2019

Cambridge, MA – September 23, 2019 – Celsius Therapeutics, a company focused on bringing personalized medicine to patients with cancer, autoimmunity and other complex diseases, today announced that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the […]
September 19

Celsius Therapeutics Signs Multiple Agreements with Academic Institutions to Access Samples for the Identification of Novel Targets in Immune Checkpoint Therapy Resistance

Celsius Applying its Single-Cell Genomics Platform Across Multiple Tumor Types and Immuno-Oncology Clinical Trials CAMBRIDGE, Mass., September 19, 2019 – Celsius Therapeutics, a company focused on bringing personalized medicine to patients with cancer, autoimmunity and other complex diseases, today announced the signing of collaboration agreements with the Parker Institute for Cancer Immunotherapy (San Francisco, USA), Institut […]
July 9

Celsius Therapeutics Signs Collaboration Agreement with Janssen to Identify Response Biomarkers for Ulcerative Colitis

Celsius to Apply its Single-Cell Genomics and Machine Learning Platform at Unprecedented Scale in Large Phase 2 Clinical Study CAMBRIDGE, Mass., July 9, 2019 – Celsius Therapeutics, a company focused on the discovery and development of precision therapeutics for patients with autoimmune diseases and cancer, today announced a collaboration with Janssen Biotech, Inc. Under the terms […]
June 11

Celsius Therapeutics Appoints Tariq Kassum, M.D., as Chief Executive Officer

Experienced biopharma leader brings business development, strategy and company-building expertise to accelerate Celsius’ growth
May 22

Celsius Therapeutics Announces Executive Leadership Team Appointments

Greg Ryslik, Ph.D., Appointed to Chief Data Officer
Michael Boretti, Ph.D., Appointed to Chief Business Officer

May 15

Celsius Therapeutics Launches with $65 Million in Series A Financing to Develop Precision Therapeutics For People with Autoimmune Diseases and Cancer

Company Created to Understand the Cellular Ecosystem of Disease Through Single-Cell Genomics

Media inquiries: media@celsiustx.com
Investor inquiries: investor@celsiustx.com

page

1 | 2

viewing per page

Geirsdottir L, David E, Keren-Shaul H, et al.

Cross-Species Single-Cell Analysis Reveals Divergence of the Primate Microglia Program.

Cell. 2019 Dec 12;179(7):1609-1622.e16. doi: 10.1016/j.cell.2019.11.010.
Huang B, Chen Z, Geng L, et al.

Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and Therapeutic Pathways.

Cell. 2019 Nov 14;179(5):1160-1176.e24. doi: 10.1016/j.cell.2019.10.027.
Martin JC, Chang C, Boschetti G, et al.

Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy.

Cell. 2019 Sep 5;178(6):1493-1508.e20. doi: 10.1016/j.cell.2019.08.008. Epub 2019 Aug 29.
Smillie CS, Biton M, Ordovas-Montanes J, et al.

Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis.

Cell. 2019 Jul 25;178(3):714-730.e22. doi: 10.1016/j.cell.2019.06.029.
Parikh K, Antanaviciute A, Fawkner-Corbett D, et al.

Colonic epithelial cell diversity in health and inflammatory bowel disease.

Nature. 2019 Mar;567(7746):49-55. doi: 10.1038/s41586-019-0992-y. Epub 2019 Feb 27.
Sade-Feldman M, Yizhak K, Bjorgaard SL, et al.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Cell. 2019 Jan 10;176(1-2):404. doi: 10.1016/j.cell.2018.12.034. No abstract available.
Li H, van der Leun A, Yofe I, et al.

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

Cell. 2018 Dec 27;176(4):775-789.e18. doi: 10.1016/j.cell.2018.11.043
Bielecki P, Riesenfeld S, Kowalczyk M, et al.

Skin inflammation driven by differentiation of quiescent tissue-resident ILCs into a spectrum of pathogenic effectors.

BioRxiv. 2018 Nov 12. doi: 10.1101/461228
Jerby-Arnon L, Shah P, Cuoco MS, et al.

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.

Cell. 2018 Nov 1;175(4):984-997.e24. doi: 10.1016/j.cell.2018.09.006.
Cohen M, Giladi A, Gorki AD, et al.

Lung Single-Cell Signaling Interaction Map Reveals Basophil Role in Macrophage Imprinting.

Cell. 2018 Nov 1;175(4):1031-1044.e18. doi: 10.1016/j.cell.2018.09.009. Epub 2018 Oct 11.
Zhang L, Yu X, Zheng L, et al.

Lineage tracking reveals dynamic relationships of T cells in colorectal cancer.

Nature. 2018 Oct 29; 564:268–272
Mizoguchi F, Slowikowski K, Wei K, et al.

Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis.

Nature Communications. 2018 Feb 23; 9(789)
Tanay A, Regev A.

Scaling single-cell genomics from phenomenology to mechanism.

Nature. 2017; 541(7637):331-338.
Stubbington MJT, Rozenblatt-Rosen O, Regev A, Teichmann SA.

Single-cell transcriptomics to explore the immune system in health and disease.

Science. 2017;358(6359):58-63.
Huang H, Fang M, Jostins L, et al.

Fine-mapping inflammatory bowel disease loci to single-variant resolution.

Nature. 2017;547(7662):173-178.
Villani AC, Satija R, Reynolds G, et al.

Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors.

Science. 2017;356(6335):pii:eaah4573.
Venteicher AS, Tirosh I, Hebert C, et al.

Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.

Science. 2017; 355(6332):eaai8478.
Puram SV, Tirosh I, Parikh AS, et al.

Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer.

Cell. 2017;171(7):1611-1624.e24.
Habib N, Li Y, Heidenreich M, et al.

Div-Seq: single-nucleus RNA-seq reveals dynamics of rare adult newborn neurons.

Science. 2016;353(6302):925-928.
Tirosh I, Izar B, Prakadan SM, et al.

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.

Science. 2016;352(6282):189-196.

PRESS RELEASES AND SCIENTIFIC PUBLICATIONS

In the News

Servier and Celsius Therapeutics Announce Target Discovery Collaboration in Colorectal Cancer

Celsius Therapeutics Signs Research Agreements with Leading Academic Centers to Develop Insights into Inflammatory Bowel Disease Biology

Jeanne Magram, Ph.D., Appointed to Chief Scientific Officer & René Russo, Pharm.D., Joins Board of Directors

FierceBiotech names Celsius Therapeutics as one of its “Fierce 15” Biotech Companies of 2019

Celsius Therapeutics Signs Multiple Agreements with Academic Institutions to Access Samples for the Identification of Novel Targets in Immune Checkpoint Therapy Resistance

Celsius Therapeutics Signs Collaboration Agreement with Janssen to Identify Response Biomarkers for Ulcerative Colitis

Celsius Therapeutics Appoints Tariq Kassum, M.D., as Chief Executive Officer

Celsius Therapeutics Announces Executive Leadership Team Appointments

Celsius Therapeutics Launches with $65 Million in Series A Financing to Develop Precision Therapeutics For People with Autoimmune Diseases and Cancer

PUBLICATIONS

Cross-Species Single-Cell Analysis Reveals Divergence of the Primate Microglia Program.

Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and Therapeutic Pathways.

Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy.

Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis.

Colonic epithelial cell diversity in health and inflammatory bowel disease.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

Skin inflammation driven by differentiation of quiescent tissue-resident ILCs into a spectrum of pathogenic effectors.

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.

Lung Single-Cell Signaling Interaction Map Reveals Basophil Role in Macrophage Imprinting.

Lineage tracking reveals dynamic relationships of T cells in colorectal cancer.

Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis.

Scaling single-cell genomics from phenomenology to mechanism.

Single-cell transcriptomics to explore the immune system in health and disease.

Fine-mapping inflammatory bowel disease loci to single-variant resolution.

Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors.

Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.

Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer.

Div-Seq: single-nucleus RNA-seq reveals dynamics of rare adult newborn neurons.

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.